Fibrinolysin

A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.

Also Known As:

Networked: 2440 relevant articles (73 outcomes, 212 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Jensen, Boye L: 19 articles (12/2020 - 02/2009)
2.	Medcalf, Robert L: 17 articles (05/2021 - 08/2009)
3.	Oda, Takashi: 15 articles (03/2022 - 07/2004)
4.	Svenningsen, Per: 15 articles (12/2020 - 02/2009)
5.	Waisman, David M: 11 articles (11/2021 - 02/2003)
6.	Marder, Victor J: 10 articles (10/2013 - 07/2002)
7.	Flick, Matthew J: 9 articles (12/2021 - 08/2014)
8.	Friis, Ulla G: 9 articles (12/2020 - 02/2009)
9.	Hattori, Koichi: 8 articles (11/2020 - 02/2012)
10.	Heissig, Beate: 8 articles (11/2020 - 02/2012)

Related Diseases

1.	Hemorrhage 04/01/2014 - "It seems that long-term prophylactic treatment with a dose of 10 IU/kg Fibrogammin could be effective in the prevention of CNS bleeding in the patients with F XIII deficiency. " 09/15/2023 - "Additionally, anti-plasmin activity can be exerted by the dissociated AA from the CSH-AA backbone, which can help to lessen secondary bleeding." 09/12/2023 - "While there is extensive literature on the optimal dosage of TXA to reduce bleeding rates and transfusion needs, it remains to be determined if these dosages also apply to blocking the non-canonical effects of plasmin." 05/22/2023 - "Inhibition of plasmin effectively reduces fibrinolysis to circumvent heavy bleeding. " 01/01/2021 - "To date, therapeutic targeting of the fibrinolytic system has been for 2 purposes: to promote plasmin generation for thromboembolic conditions or to stop plasmin to reduce bleeding. "
2.	Vitreous Detachment (Posterior Vitreous Detachment) 01/01/2016 - "Plasmin can successfully cause vitreous liquefaction and induce a posterior vitreous detachment. " 01/01/2012 - "Plasmin plus SF(6) injection resulted in complete posterior vitreous detachment (PVD), whereas plasmin or SF(6) injection alone resulted in only partial PVD. " 03/01/2009 - "Intravitreal plasmin creates a posterior vitreous detachment, but may also liquefy the vitreous. " 06/01/2008 - "The use of plasmin for pharmacologic vitreolysis and the creation of a posterior vitreous detachment offers several potential advantages over surgery. " 10/01/2005 - "Our results suggested that activation of endogenous MMP-2 by exogenous plasmin is associated with the induction of posterior vitreous detachment."
3.	Neoplasms (Cancer) 02/28/2015 - "Molecular modeling studies showed that NC1(XIX) and the anti-tumor fragment released by plasmin (F4) adopted locally the same type I β-turn conformation. " 12/01/2011 - "The present study revealed that plasmin was present in tumor tissue, and that it was responsible for processing progalanin to galanin(1-20) in the extracellular environment." 04/02/2010 - "Because plasmin activity controls fibrinolysis in a variety of pathological conditions, including cancer and wound healing, several intervention studies have focused on targeting the uPA.uPAR interaction in vivo. " 05/19/1997 - "In this study we have used mice lacking components of the PA/plasmin system to analyze the role of this system in the transformation process and in tumor growth. " 05/01/1996 - "It is concluded that these three cell lines constitute a valuable model system for in vitro studies of the role of cell surface uPA in cancer cell invasion and has application in the search for novel compounds which inhibit mechanisms involved in uPA-mediated plasmin generation on cancer cells."
4.	Thrombosis (Thrombus) 07/01/2009 - "Locally delivered plasmin may have similar thrombolytic efficacy with a superior safety profile, so herein it was compared with TPA in a porcine model of AV graft thrombosis. " 11/01/1992 - "It was established that the efficacy of prophylactic of thrombosis by plasmin only was low: middle ball of thrombosis was 2.5-3.0. " 01/01/1985 - "To investigate the possibility that 99mTc-labelled acylplasmins are improved thrombus-detecting agents, six acylating agents were synthesised and their reaction with plasmin and the labelling of the products with 99mTc studies. " 01/01/1993 - "Results of recent studies suggest that recurrent thrombosis may be due to multiple factors including: plasmin-mediated activation of the coagulation system, procoagulant activity of the residual thrombus, presence of high shear forces that promote platelet deposition, and attenuation of physiologic fibrinolytic activity after pharmacologic thrombolysis. " 12/11/1958 - "[Studies on fibrinolysin activities in thrombosis]."
5.	Inflammation (Inflammations) 04/01/2016 - "However, recent studies have linked an excess of plasmin generated by this interaction with serious pathological events at the vascular level, including the proliferation and migration of arterial wall cells, inflammation, and degradation of the extracellular matrix. " 01/01/2021 - "In conclusion, these results suggest that fibrinolysis through plasmin is essential for skeletal growth and maintenance, and is multifactorial by limiting inflammation and preserving vasculature." 12/01/2020 - "Plasmin is generally known as a promotor of inflammation. " 01/01/2019 - "Plasmin-mediated fibrinolysis enables macrophage migration in a murine model of inflammation." 09/01/2012 - "However, beyond fibrinolysis, plasmin has a number of crucial functions in a variety of processes, including inflammation. "

Related Drugs and Biologics

1.	Thrombin
2.	Fibrin
3.	Enzymes
4.	Antifibrinolytic Agents (Antifibrinolytics)
5.	Fibrinogen (Factor I)
6.	Plasminogen
7.	alpha-2-Antiplasmin (alpha 2 Antiplasmin)
8.	estropipate (Ogen)
9.	Peptide Hydrolases (Proteases)
10.	fibrin fragment D (D-dimer)

Related Therapies and Procedures

1.	Therapeutics
2.	Vitrectomy
3.	Intravitreal Injections
4.	Catheters
5.	Ligation